MedPath
HSA Approval

EMTHEXATE 2.5 TABLET 2.5 mg

SIN12414P

EMTHEXATE 2.5 TABLET 2.5 mg

EMTHEXATE 2.5 TABLET 2.5 mg

August 30, 2003

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

L01BA01

methotrexate

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA CZECH INDUSTRIES S.R.O

Active Ingredients

METHOTREXATE DISODIUM EQV METHOTREXATE

2.5 mg

Methotrexate

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

EMTHEXATE 2.5 TABLET 2.5 mg - HSA Approval | MedPath